{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:10:34Z","timestamp":1785859834007,"version":"3.56.0"},"reference-count":50,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German research Association","doi-asserted-by":"crossref","award":["5779\/5-1 JWM"],"award-info":[{"award-number":["5779\/5-1 JWM"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German research Association","doi-asserted-by":"crossref","award":["DFG"],"award-info":[{"award-number":["DFG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German research Association","doi-asserted-by":"crossref","award":["DFG 5779\/2-3 JWM"],"award-info":[{"award-number":["DFG 5779\/2-3 JWM"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To investigate the therapeutic potential of caspase-1 inhibition in systemic lupus erythematosus (SLE) and lupus nephritis (LN) using the MRL-\n                      <jats:italic>\n                        Fas\n                        <jats:sup>lpr<\/jats:sup>\n                      <\/jats:italic>\n                      mouse model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Female Murphy Roths large (MRL)-\n                      <jats:italic>\n                        Fas\n                        <jats:sup>lpr<\/jats:sup>\n                      <\/jats:italic>\n                      mice were treated with a caspase-1 inhibitor (pralnacase) or sham treatment from 2.5 to 5.5 months of age. Disease progression was assessed through analysis of systemic and renal parameters, including proteinuria, blood urea nitrogen, kidney histopathology and immune cell infiltration. Cytokine expression and caspase activity were measured to elucidate the mechanism of action. Additional experiments with interleukin (IL)-1 receptor antagonist and pancaspase inhibition treatment as well as post-disease onset intervention were conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Caspase-1 inhibition significantly reduced systemic inflammation, lymphadenopathy and skin lesions in MRL-\n                      <jats:italic>\n                        Fas\n                        <jats:sup>lpr<\/jats:sup>\n                      <\/jats:italic>\n                      mice. Treated mice exhibited decreased proteinuria, improved renal function and reduced kidney pathology. The treatment specifically targeted caspase-1 activity, leading to decreased IL-18 levels as well as attenuated immune cell activation and infiltration in the kidneys. Selective caspase-1 inhibition showed comparable results with pancaspase inhibition. IL-1 receptor antagonist treatment did not significantly affect disease progression, suggesting IL-18 as the primary driver of pathology. Post-disease onset intervention with caspase-1 inhibition also showed efficacy, although to a lesser extent than pre-onset treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Caspase-1 inhibition effectively ameliorates both systemic and renal manifestations of SLE in MRL-\n                      <jats:italic>\n                        Fas\n                        <jats:sup>lpr<\/jats:sup>\n                      <\/jats:italic>\n                      mice, primarily through suppression of IL-18-mediated inflammation. This study identifies caspase-1 as a promising therapeutic target for SLE and LN, warranting further investigation in clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006194","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T20:00:19Z","timestamp":1766520019000},"page":"e006194","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-\n                    <i>\n                      Fas\n                      <sup>lpr<\/sup>\n                    <\/i>\n                    mice and delays systemic illness"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-0525","authenticated-orcid":false,"given":"Paul","family":"Cla\u00dfen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Meineck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Plath","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Saurin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fasola","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pautz","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"Acura Rheumatology Center Rhineland-Palatinate, Bad-Kreuznach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone Cosima","family":"Boedecker-Lips","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany"},{"name":"Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, RP, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2025122312000943000_11.4.e006194.1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020"},{"key":"2025122312000943000_11.4.e006194.2","first-page":"225","article-title":"Lupus nephritis: from diagnosis to treatment","volume":"64","author":"Weinmann-Menke","year":"2023","journal-title":"Inn Med (Heidelb)"},{"key":"2025122312000943000_11.4.e006194.3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616"},{"key":"2025122312000943000_11.4.e006194.4","doi-asserted-by":"crossref","DOI":"10.1080\/08916934.2024.2319203","article-title":"Animal models of lupus nephritis: the past, present and a future outlook","volume":"57","author":"Katikaneni","year":"2024","journal-title":"Autoimmunity"},{"key":"2025122312000943000_11.4.e006194.5","doi-asserted-by":"publisher","DOI":"10.1006\/meth.1999.0837"},{"key":"2025122312000943000_11.4.e006194.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02588.x"},{"key":"2025122312000943000_11.4.e006194.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.10563"},{"key":"2025122312000943000_11.4.e006194.8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.438"},{"key":"2025122312000943000_11.4.e006194.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01250","article-title":"Analysis of Serum Interleukin (IL)-1\u03b2 and IL-18 in Systemic Lupus Erythematosus","volume":"9","author":"Mende","year":"2018","journal-title":"Front Immunol"},{"key":"2025122312000943000_11.4.e006194.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1386-6"},{"key":"2025122312000943000_11.4.e006194.11","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2010.0210"},{"key":"2025122312000943000_11.4.e006194.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.10.1078"},{"key":"2025122312000943000_11.4.e006194.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.15171\/jnp.2016.05","article-title":"Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus","volume":"5","author":"Jafari-Nakhjavani","year":"2016","journal-title":"J Nephropathol"},{"key":"2025122312000943000_11.4.e006194.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.3757"},{"key":"2025122312000943000_11.4.e006194.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.8.5312"},{"key":"2025122312000943000_11.4.e006194.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev269"},{"key":"2025122312000943000_11.4.e006194.17","first-page":"109","article-title":"IL-1 beta-deficient mice are resistant to induction of experimental SLE","volume":"17","author":"Voronov","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"2025122312000943000_11.4.e006194.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1525-z","article-title":"IL-1 family cytokines and soluble receptors in systemic lupus erythematosus","volume":"20","author":"Italiani","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025122312000943000_11.4.e006194.19","first-page":"411","article-title":"Serum and urinary cytokine levels of SLE patients","volume":"67","author":"Brugos","year":"2012","journal-title":"Pharmazie"},{"key":"2025122312000943000_11.4.e006194.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket428"},{"key":"2025122312000943000_11.4.e006194.21","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0000000000000085"},{"key":"2025122312000943000_11.4.e006194.22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.reumae.2019.10.004","article-title":"Role of Inflammasome Activation in Systemic Lupus Erythematosus: Are Innate Immune Cells Activated?","volume":"17","author":"Perez-Alamino","year":"2021","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"2025122312000943000_11.4.e006194.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101284"},{"key":"2025122312000943000_11.4.e006194.24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402044"},{"key":"2025122312000943000_11.4.e006194.25","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.1997.0618"},{"key":"2025122312000943000_11.4.e006194.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415756111"},{"key":"2025122312000943000_11.4.e006194.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.02.015"},{"key":"2025122312000943000_11.4.e006194.28","first-page":"222","article-title":"Effects of caspase inhibitor z-VAD-fmk on the expressions of calumenin, caspase-3, GRP78 and GRP94 in adriamycin-injured cardiomyocytes","volume":"33","author":"Bao","year":"2017","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"key":"2025122312000943000_11.4.e006194.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2452"},{"key":"2025122312000943000_11.4.e006194.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.720877","article-title":"Novel Effects of Combination Therapy Through Inhibition of Caspase-1\/Gasdermin D Induced-Pyroptosis in Lupus Nephritis","volume":"12","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"2025122312000943000_11.4.e006194.31","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000088"},{"key":"2025122312000943000_11.4.e006194.32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/art.38225","article-title":"An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage","volume":"66","author":"Kahlenberg","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025122312000943000_11.4.e006194.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(03)00153-5"},{"key":"2025122312000943000_11.4.e006194.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-04240-3","article-title":"A long way to go: caspase inhibitors in clinical use","volume":"12","author":"Dhani","year":"2021","journal-title":"Cell Death Dis"},{"key":"2025122312000943000_11.4.e006194.35","unstructured":"Pavelka K , Kua V , Moeller Rasmussen J , et al . Clinical effects of pralnacasan (PRAL), an orally-active interleukin-1\u03b2 converting enzyme (ICE) inhibitor, in a 285 patient phII trial in rheumatoid arthritis (RA). Arthritis Rheum 2001."},{"key":"2025122312000943000_11.4.e006194.36","first-page":"473","article-title":"Pharmacological caspase inhibitors: research towards therapeutic perspectives","volume":"66","author":"Kudelova","year":"2015","journal-title":"J Physiol Pharmacol"},{"key":"2025122312000943000_11.4.e006194.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3915"},{"key":"2025122312000943000_11.4.e006194.38","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013121356"},{"key":"2025122312000943000_11.4.e006194.39","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018090901"},{"key":"2025122312000943000_11.4.e006194.40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.55563\/clinexprheumatol\/eakvlv","article-title":"Activation of caspase-1 is mediated by stimulation of interferon genes and NLR family pyrin domain containing 3 in monocytes of active systemic lupus erythematosus","volume":"40","author":"Inokuchi","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025122312000943000_11.4.e006194.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221985"},{"key":"2025122312000943000_11.4.e006194.42","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.2.151"},{"key":"2025122312000943000_11.4.e006194.43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954706"},{"key":"2025122312000943000_11.4.e006194.44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bbrc.2019.03.202","article-title":"Caspase-1 inhibition mediates neuroprotection in experimental stroke by polarizing M2 microglia\/macrophage and suppressing NF-\u03baB activation","volume":"513","author":"Li","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"2025122312000943000_11.4.e006194.45","doi-asserted-by":"crossref","DOI":"10.1038\/srep46652","article-title":"Elevated circulating levels of the interferon-\u03b3-induced chemokines are associated with disease activity and cutaneous manifestations in adult-onset Still\u2019s disease","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"2025122312000943000_11.4.e006194.46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/jlb.63.6.658","article-title":"Overview of interleukin-18: more than an interferon-gamma inducing factor","volume":"63","author":"Dinarello","year":"1998","journal-title":"J Leukoc Biol"},{"key":"2025122312000943000_11.4.e006194.47","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-04966-8","article-title":"Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis","volume":"13","author":"Jin","year":"2022","journal-title":"Cell Death Dis"},{"key":"2025122312000943000_11.4.e006194.48","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02985-x","article-title":"NLRP3 inflammasome in endothelial dysfunction","volume":"11","author":"Bai","year":"2020","journal-title":"Cell Death Dis"},{"key":"2025122312000943000_11.4.e006194.49","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-07-0628"},{"key":"2025122312000943000_11.4.e006194.50","doi-asserted-by":"crossref","first-page":"111256","DOI":"10.1016\/j.intimp.2023.111256","article-title":"Mesenchymal stem cells attenuate systemic lupus erythematosus by inhibiting NLRP3 inflammasome activation through Pim-1 kinase","volume":"126","author":"Yu","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T20:00:23Z","timestamp":1766520023000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-006194"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006194","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}